In 2007, Broniscer et al. determined the MTD and DLTs of escalating doses of TMZ combined with fixed doses of O6-benzylguanine, a pseudosubstrate of MGMT, in a phase I study in children with recurrent brain tumors. Here, MGMT is linked to brain neoplasm.